References
- SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin201262102922237781
- AzzoliCGBakerSJrTeminS[American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.]Zhongguo Fei Ai Za Zhi200913171189 Chinese20681066
- D’AddarioGFruhMReckMBaumannPKlepetkoWFelipEMetastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201021Suppl 5v116v11920555059
- National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology: non-small cell lung cancer. Version 2.2013 Available from: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfAccessed March 21, 2013
- LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med20043502129213915118073
- PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience20043041497150015118125
- PaoWMillerVZakowskiMEGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProc Natl Acad Sci USA2004101133061331115329413
- RosellRMoranTQueraltCScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med200936195896719692684
- Cortes-FunesHGomezCRosellREpidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patientsAnn Oncol2005161081108615851406
- MitsudomiTKosakaTEndohHMutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrenceJ Clin Oncol2005232513252015738541
- HanSWKimTYJeonYKOptimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylationClin Cancer Res2006122538254416638863
- InoueASuzukiTFukuharaTProspective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutationsJ Clin Oncol2006243340334616785471
- SugioKUramotoHOnitsukaTProspective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutationsLung Cancer20096431431818992959
- SunagaNTomizawaYYanagitaniNPhase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapyLung Cancer20075638338917368623
- SutaniANagaiYUdagawaKGefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clampBr J Cancer2006951483148917106442
- TamuraKOkamotoIKashiiTMulticentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)Br J Cancer20089890791418283321
- YoshidaKYatabeYParkJYProspective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancerJ Thorac Oncol20072222817410005
- SequistLVMartinsRGSpigelDFirst-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutationsJ Clin Oncol2008262442244918458038
- MoritaSOkamotoIKobayashiKCombined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutationsClin Cancer Res2009154493449819531624
- JackmanDMMillerVACioffrediLAImpact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trialsClin Cancer Res2009155267527319671843
- HanJYParkKKimSWFirst-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJ Clin Oncol2012301122112822370314
- MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936194795719692680
- FukuokaMWuYLThongprasertSBiomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)J Clin Oncol2011292866287421670455
- GridelliCDe MarinisFDi MaioMCortinovisDCappuzzoFMokTGefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: implications for clinical practice and open issuesLung Cancer2011723821216488
- MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol20101112112820022809
- MitsudomiTMoritaSYatabeYUpdated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR)J Clin Oncol201230Suppl7521
- MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med20103622380238820573926
- InoueAKobayashiKMaemondoMUpdated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)Ann Oncol201324545922967997
- OizumiSKobayashiKInoueAQuality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 TrialOncologist20121786387022581822
- ZhouCWuYLChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol20111273574221783417
- YangJCHSchulerMHYamamotoNLUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutationsJ Clin Oncol201230SupplLBA7500
- RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol20121323924622285168
- TakanoTFukuiTOheYEGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in JapanJ Clin Oncol2008265589559518794545
- KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med200535278679215728811
- PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med20052e7315737014
- BalakMNGongYRielyGJNovel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitorsClin Cancer Res2006126494650117085664
- KosakaTYatabeYEndohHAnalysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinibClin Cancer Res2006125764576917020982
- ToyookaSKiuraKMitsudomiTEGFR mutation and response of lung cancer to gefitinibN Engl J Med20053522136 author reply 213615901872
- HallJGEisPSLawSMSensitive detection of DNA polymorphisms by the serial invasive signal amplification reactionProc Natl Acad Sci USA2000978272827710890904
- NagaiYMiyazawaHHuqunGenetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clampCancer Res2005657276728216105816
- MaheswaranSSequistLVNagrathSDetection of mutations in EGFR in circulating lung-cancer cellsN Engl J Med200835936637718596266
- SuKYChenHYLiKCPretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancerJ Clin Oncol20123043344022215752
- BranfordSRudzkiZWalshSHigh frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceBlood2002993472347511964322
- TamboriniEBonadimanLGrecoAA new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patientGastroenterology200412729429915236194
- KumarAPetriETHalmosBBoggonTJStructure and clinical relevance of the epidermal growth factor receptor in human cancerJ Clin Oncol2008261742175118375904
- YunCHMengwasserKETomsAVThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProc Natl Acad Sci USA20081052070207518227510
- LiDAmbrogioLShimamuraTBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene2008274702471118408761
- EngelmanJAZejnullahuKGaleCMPF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibCancer Res200767119241193218089823
- GonzalesAJHookKEAlthausIWAntitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitorMol Cancer Ther200871880188918606718
- SosMLRodeHBHeynckSChemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutationCancer Res20107086887420103621
- TakezawaKOkamotoITanizakiJEnhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptorMol Cancer Ther201091647165620530710
- RegalesLGongYShenRDual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancerJ Clin Invest20091193000301019759520
- ShimamuraTLiDJiHHsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistanceCancer Res2008685827583818632637
- ZhouWErcanDChenLNovel mutant-selective EGFR kinase inhibitors against EGFR T790MNature20094621070107420033049
- EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience20073161039104317463250
- OuSHIGovindanREatonKDPhase I/II dose-finding study of crizotinib (criz) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC)J Clin Oncol201230Suppl2610
- YoshidaTOkamotoIOkamotoWEffects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplificationCancer Sci201010116717219804422
- OkabeTOkamotoITsukiokaSAddition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplificationClin Cancer Res20091590791319188161
- MorgilloFWooJKKimESHongWKLeeHYHeterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinibCancer Res200666101001011117047074
- MorgilloFKimWYKimESCiardielloFHongWKLeeHYImplication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinibClin Cancer Res2007132795280317473213
- GuixMFaberACWangSEAcquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteinsJ Clin Invest20081182609261918568074
- SosMLKokerMWeirBAPTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFRCancer Res2009693256326119351834
- YamasakiFJohansenMJZhangDAcquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated AktCancer Res2007675779578817575145
- ZakowskiMFLadanyiMKrisMGMemorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome GroupEGFR mutations in small-cell lung cancers in patients who have never smokedN Engl J Med200635521321516837691
- ArcilaMEOxnardGRNafaKRebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assayClin Cancer Res2011171169118021248300
- MorinagaROkamotoIFurutaKSequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutationLung Cancer20075841141317601631
- YanoSWangWLiQHepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutationsCancer Res2008689479948719010923
- YaoZFenoglioSGaoDCTGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancerProc Natl Acad Sci USA2010107155351554020713723
- SudaKTomizawaKFujiiMEpithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinibJ Thorac Oncol201161152116121597390
- UramotoHShimokawaHHanagiriTKuwanoMOnoMExpression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinomaLung Cancer20113025132517
- SequistLVWaltmanBADias-SantagataDGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsSci Transl Med2011375ra26
- PalmerRHVernerssonEGrabbeCHallbergBAnaplastic lymphoma kinase: signalling in development and diseaseBiochem J200942034536119459784
- ManoHNon-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancerCancer Sci2008992349235519032370
- SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature200744856156617625570
- ChoiYLTakeuchiKSodaMIdentification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancerCancer Res2008684971497618593892
- TakeuchiKChoiYLSodaMMultiplex reverse transcription-PCR screening for EML4-ALK fusion transcriptsClin Cancer Res2008146618662418927303
- TakeuchiKChoiYLTogashiYKIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancerClin Cancer Res2009153143314919383809
- SolomonBVarella-GarciaMCamidgeDRALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancerJ Thorac Oncol200941450145420009909
- KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med20103631693170320979469
- WongDWLeungELSoKKThe EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRASCancer20091151723173319170230
- TiseoMGelsominoFBoggianiDEGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutationsLung Cancer20117124124321168933
- Mino-KenudsonMChirieacLRLawKA novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistryClin Cancer Res2010161561157120179225
- RodigSJMino-KenudsonMDacicSUnique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western populationClin Cancer Res2009155216522319671850
- YoshidaATsutaKNakamuraHComprehensive histologic analysis of ALK-rearranged lung carcinomasAm J Surg Pathol2011351226123421753699
- LinELiLGuanYExon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancersMol Cancer Res200971466147619737969
- SugawaraETogashiYKurodaNIdentification of anaplastic lymphoma kinase fusions in renal cancer: large-scale immunohistochemical screening by the intercalated antibody-enhanced polymer methodCancer20121184427443622252991
- ChristensenJGZouHYArangoMECytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaMol Cancer Ther200763314332218089725
- ZouHYLiQLeeJHAn orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanismsCancer Res2007674408441717483355
- CamidgeDRBangYJKwakELActivity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1studyLancet Oncol2012131011101922954507
- ShawATKimDWNakagawaKPhase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) (PROFILE 1007)Ann Oncol201223Suppl 9ixe21
- KimDWAhnMJShiYUpdated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancerAnn Oncol201223Suppl 9ix400ix446
- SakamotoHTsukaguchiTHiroshimaSCH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutantCancer Cell20111967969021575866
- KiuraKSetoTYamamotoNA first-in-human phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLCJ Clin Oncol201230Suppl7602
- NishioMKiuraKNakagawaKA phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLC; safety and efficacy interim results of the phase II portionAnn Oncol201223Suppl 9ix152ix174
- ShawATCamidgeDRFelipEResults of a first-in-human phase I study of the ALK INHIBITOR LDK378 in advanced solid tumorsAnn Oncol201223Suppl 9ix152ix174
- CecconMMologniLBissonWScapozzaLGambacorti-PasseriniCCrizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitorsMol Cancer Res20121112213223239810
- KatayamaRKhanTMBenesCTherapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProc Natl Acad Sci USA20111087535754021502504
- GettingerSWeissGJSalgiaRA first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignanciesAnn Oncol201223Suppl 9ix152ix174
- LovlyCMHeuckmannJMde StanchinaEInsights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitorsCancer Res2011714920493121613408
- KuromitsuSMoriMShimadaIAntitumor activities of ASP3026 against EML4-ALK-dependent tumor modelsMol Cancer Ther201110SupplA227